Fosamax Osteonecrosis of the Jaw Settlement: Washington Injury Lawyer

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science information has served as a foundational resource for public awareness, offering broad guidance on wellness, disease prevention, and the safe use of medications. This legacy context naturally includes discussions of prescription drug benefits and potential side effects, helping individuals make informed decisions about their care. Within this framework, the transition from general health education to more specific exposure concerns emerges when a widely used medication becomes associated with a rare but serious adverse event. In the case of bisphosphonate therapies like Fosamax, originally prescribed to manage bone density loss, the focus shifts from routine therapeutic use to the recognition of a distinct risk: osteonecrosis of the jaw. This condition, involving bone tissue death in the jaw, has prompted legal and medical scrutiny, particularly for patients with prolonged exposure. The pivot from general health information to occupational exposure concern is subtle but critical. While the general public may encounter Fosamax through standard prescribing practices, certain populations—such as those in healthcare or dental fields—may face heightened awareness or indirect exposure risks. This transition underscores the need to move beyond broad health literacy toward targeted vigilance, especially when medication use intersects with professional environments where jaw health is routinely assessed. The legacy of general health information thus provides a necessary backdrop for understanding how a common therapy can lead to specialized legal and medical considerations.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed to treat osteoporosis and other bone conditions. A known adverse effect associated with Fosamax use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures. This section examines the clinical presentation, pharmacological mechanisms, and risk considerations for patients affected by Fosamax-related ONJ, with a focus on Washington state legal and settlement contexts. Osteonecrosis of the jaw presents as exposed bone in the oral cavity that fails to heal within eight weeks after identification. The condition is generally associated with tooth extraction, local infection, or delayed healing following dental surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures such as tooth extraction, dental implants, and boney surgery; diagnosis of cancer; concomitant therapies including chemotherapy, corticosteroids, and angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Multiscale characterization of jawbone tissue provides comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Pharmacology and Reported Adverse Effects

Fosamax (alendronate) works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism, while beneficial for osteoporosis, can impair the jawbone's ability to remodel and heal after minor trauma or dental procedures. The time to onset of ONJ symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, while atypical femoral fractures are uncommon (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathway linking Fosamax to ONJ involves suppression of bone turnover in the jaw, which has a high rate of remodeling due to daily mechanical stress from chewing and the presence of teeth. Bisphosphonates accumulate in bone and inhibit osteoclast activity, reducing the ability to remove necrotic bone and impairing healing after dental procedures or infection. The jawbone's unique structure and blood supply make it particularly susceptible to this effect (https://pubmed.ncbi.nlm.nih.gov/40345077/). The condition can occur spontaneously but is generally associated with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Settlement Considerations

The FDA-approved labeling for Fosamax includes a warning about ONJ under section 5.4, stating that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Clinical judgment of the treating physician and/or oral surgeon should guide the management plan based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon, and extensive dental surgery to treat ONJ may exacerbate the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients in Washington state who have developed ONJ after taking Fosamax, settlement considerations may include the adequacy of warnings provided by the manufacturer. The FDA-approved labeling includes warnings about ONJ, but patients may argue that these warnings were insufficient to alert prescribers and patients to the risk, particularly given that the condition can occur spontaneously and the time to onset varies widely (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), and patients who have taken Fosamax for extended periods may have a stronger claim. Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/), which may inform decisions about drug holidays.

Timeline Between Exposure and Documented Harm

The timeline between Fosamax exposure and ONJ onset can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a causal link in individual cases. The condition is rare, with incidence rates that are low compared to other bisphosphonate-related adverse effects (https://pubmed.ncbi.nlm.nih.gov/42046648/). Patients who develop ONJ should seek care from an oral surgeon, and discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. It can cause osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and fails to heal, often after dental procedures. The risk increases with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the symptoms and risk factors for Fosamax-related ONJ?

Symptoms include exposed bone in the mouth that doesn't heal within eight weeks. Risk factors include dental surgery, poor oral hygiene, cancer, and certain medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long after starting Fosamax can ONJ occur?

ONJ can occur from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Are there adequate warnings about ONJ on Fosamax labels?

The FDA label includes a warning about ONJ, but some argue it is insufficient given the risk can occur spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What should I do if I develop ONJ while taking Fosamax?

Consult an oral surgeon and discuss discontinuing bisphosphonate therapy with your doctor based on individual risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.